Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia
- 503 Downloads
Vitamin D insufficiency is prevalent in osteopenic and osteoporotic postmenopausal women. The persistent increase in circulating parathyroid hormone (PTH) caused by vitamin D insufficiency reduces bone density response to antiresorptive agents in these postmenopausal women. It is not well known whether administration of raloxifene might increase serum PTH secondary to the suppression of serum calcium in postmenopausal women with osteopenia or osteoporosis. We tried to assess whether raloxifene might affect serum PTH and whether the addition of alfacalcidol to raloxifene therapy could have favorable effects on bone mineral density (BMD) and bone turnover as compared to raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia (≤2.0 SD based on young Japanese women). A total of 169 subjects were randomly assigned to groups receiving 60 mg raloxifene (R), or 1 μg alfacalcidol (D), or a combination of both (R + D) for 2 years. Serum levels of 25-hydroxyvitamin D [25(OH)D] were measured at randomization. The modified ‘intention to treat’ method was used. We compared the groups using a Tukey–Kramer test for changes in L- and TH-BMD and calcium metabolism when significant differences were found using one-way ANOVA. The parameters in each group during the experimental period were analyzed by means of paired t tests. Baseline 25(OH)D and i-PTH were 23.7 ng/ml and 38.4 pg/ml, respectively. At 6 months, i-PTH demonstrated a significant increase (+21.0%) in the R-group whereas significant decreases in i-PTH were observed in the D-group and combination-group (−15.9 and −8.9%, respectively). There were significant increases in L-BMD in the R + D-group (+4.1% at 1 year and +4.7% at 2 years, P < 0.0001) and in the R-group (+2.9% at 1 year and +2.8% at 2 years, P < 0.001), but the difference between the groups did not reach a significant level. Vitamin D status at randomization did not affect the subsequent BMD response in coadministration of alfacalcidol with raloxifene. Supplementation with alfacalcidol to raloxifene therapy demonstrates a greater bone-sparing effect by suppressing the secondary increment of serum PTH than when raloxifene is used alone.
KeywordsRaloxifene Alfacalcidol Bone density Vitamin D PTH
Conflict of interest
I.G. has received honoraria for lectures from Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
- 18.Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) A superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425–434PubMedCrossRefGoogle Scholar
- 27.Hollis BW, Kamerud JQ, Selvaag SR et al. (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39:529–533Google Scholar
- 28.Fillee C et al (2008) Validation of the Beckman Coulter Unicel® DxI 800 for intra-operative and routine intact parathyroid hormone assay: A073. Clin Chem Lab Med 46:A168Google Scholar
- 30.Heaney RP (2004) Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 80 (suppl):1706S–1709SGoogle Scholar
- 40.Brown EM, Pollak M, Seidman CE et al. (1995) Calcium-ion-sensing cell-surface receptors. N Engl J Med 333:234–240Google Scholar
- 41.Garnero P, Munoz F, Somay-Rendu E, Delmas PD (2007) Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone (NY) 40:716–722Google Scholar
- 44.Need AG, Nordin BEC (2008) Misconceptions: Vitamin D insufficiency causes malabsorption of calcium. Bone (NY) 42:1021–1024Google Scholar